Thomas Bo Bjorn Klee, managing director of Lundbeck UK and Ireland, describes the global restructuring program Lundbeck initiated two years ago to ensure value creation, build on unique strengths and meet current health needs. Lundbeck is now focused on four key CNS areas: depression, schizophrenia, Alzheimer’s disease and Parkinson’s disease. Klee highlights the UK as one of Lundbeck’s primary markets and emphasizes the country’s continuing relevance from a strategic R&D point of view.
Can you start by elaborating on the historical presence of Lundbeck´s affiliate in the UK?
"The new, focused strategy equips us to build on our CNS heritage and expertise, remain patient-focused and meet current health needs here in the UK"
